M
M. William Audeh
Researcher at Cedars-Sinai Medical Center
Publications - 23
Citations - 3993
M. William Audeh is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Breast cancer & Internal medicine. The author has an hindex of 9, co-authored 14 publications receiving 3546 citations. Previous affiliations of M. William Audeh include Rabin Medical Center.
Papers
More filters
Journal ArticleDOI
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Andrew Tutt,Mark E. Robson,Judy Garber,Susan M. Domchek,M. William Audeh,Jeffrey N. Weitzel,Michael Friedlander,Banu Arun,Niklas Loman,Rita K. Schmutzler,Andrew M Wardley,Gillian Mitchell,H. M. Earl,Mark Wickens,James Carmichael +14 more
TL;DR: Findings from this phase 2 study provide positive proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer.
Journal ArticleDOI
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman,Ronnie Shapira-Frommer,Rita K. Schmutzler,M. William Audeh,Michael Friedlander,Judith Balmaña,Gillian Mitchell,Georgeta Fried,Salomon M. Stemmer,Ayala Hubert,Ora Rosengarten,Mariana Steiner,Niklas Loman,Karin Bowen,Anitra Fielding,Susan M. Domchek +15 more
TL;DR: Responses to olaparib were observed across different tumor types associated with germline BRCA1/2 mutations, and warrants further investigation in confirmatory studies.
Journal ArticleDOI
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Susan M. Domchek,Carol Aghajanian,Ronnie Shapira-Frommer,Rita K. Schmutzler,M. William Audeh,Michael Friedlander,Judith Balmaña,Gillian Mitchell,Gillian Mitchell,Georgeta Fried,Salomon M. Stemmer,Ayala Hubert,Ora Rosengarten,Niklas Loman,Jane Robertson,Helen Mann,Bella Kaufman +16 more
TL;DR: Following ≥3 prior lines of chemotherapy, olaparib 400mg bid (capsule form) monotherapy demonstrated notable antitumor activity in patients with gBRCA1/2m advanced ovarian cancer and no new safety signals were identified.
Journal ArticleDOI
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
TL;DR: Many “sporadic” cases of TNBC appear to have indicators of DNA repair dysfunction similar to those in BRCA-mutation carriers, suggesting the possible utility of PARP inhibitors in a subset of T NBC.
Journal ArticleDOI
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
David M. Hyams,Arlene Chan,Celia de Oliveira,Raymond Snyder,Jeferson Vinholes,M. William Audeh,Victor M. Alencar,Janine Lombard,Bijoyesh Mookerjee,Bijoyesh Mookerjee,John Xu,Kathryn H. Brown,P Klein +12 more
TL;DR: Cediranib plus fulvestrant may demonstrate clinical activity in this population of hormone-sensitive metastatic breast cancer, but cedIRanib 45 mg was not sufficiently well tolerated and Investigation of lower doses of cedirAnib plus hormonal/chemotherapy could be considered.